66 related articles for article (PubMed ID: 20809295)
1. [Second line AUO study AB35/09 of metastasized urothelial cell carcinoma].
Rexer H
Urologe A; 2010 Sep; 49(9):1194-5. PubMed ID: 20809295
[No Abstract] [Full Text] [Related]
2. [Second line AUO (Working Group Urological Oncology) study AB 35/09 on metastasized urothelial carcinoma. Phase II study with RAD001 in combination with paclitaxel for patients with metastasized urothelial carcinoma of the urinary bladder after failure of platinum-based chemotherapy (CRAD001)].
Rexer H
Urologe A; 2011 Nov; 50(11):1464-5. PubMed ID: 22042448
[No Abstract] [Full Text] [Related]
3. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
[TBL] [Abstract][Full Text] [Related]
4. Review and outlook for the role of paclitaxel in urothelial carcinoma.
Vaughn DJ
Semin Oncol; 1999 Feb; 26(1 Suppl 2):117-22. PubMed ID: 10190793
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies.
Tu SM; Hossan E; Amato R; Kilbourn R; Logothetis CJ
J Urol; 1995 Nov; 154(5):1719-22. PubMed ID: 7563331
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group.
Vaughn DJ; Manola J; Dreicer R; See W; Levitt R; Wilding G
Cancer; 2002 Sep; 95(5):1022-7. PubMed ID: 12209686
[TBL] [Abstract][Full Text] [Related]
7. Editorial comment to paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
El-Gamal OM
Int J Urol; 2011 May; 18(5):357. PubMed ID: 21453399
[No Abstract] [Full Text] [Related]
8. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
[TBL] [Abstract][Full Text] [Related]
10. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy of urothelial tumors of the bladder].
Culine S; Guastalla JP; Théodore C; Droz JP
Bull Cancer Radiother; 1994; 81(4):303-11. PubMed ID: 7702915
[No Abstract] [Full Text] [Related]
12. Paclitaxel in head and neck cancer and other tumor types: chairmen's introduction.
Cortés-Funes H; Aisner J
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-51-S2-57. PubMed ID: 9045338
[No Abstract] [Full Text] [Related]
13. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
Tsai YS; Tzai TS; Chow NH
Urol Int; 2007; 79(3):210-6. PubMed ID: 17940352
[TBL] [Abstract][Full Text] [Related]
14. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
[TBL] [Abstract][Full Text] [Related]
15. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
Kouno T; Ando M; Yonemori K; Matsumoto K; Shimizu C; Katsumata N; Komiyama M; Okajima E; Matsuoka N; Fujimoto H; Fujiwara Y
Eur Urol; 2007 Oct; 52(4):1115-22. PubMed ID: 17433855
[TBL] [Abstract][Full Text] [Related]
16. Systemic chemotherapy of carcinoma of the urinary bladder.
Maral J; Chamseddine N; Auclerc G; Jacquillat C
Prog Clin Biol Res; 1984; 162B():107-12. PubMed ID: 6542216
[No Abstract] [Full Text] [Related]
17. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ-preserving therapy in carefully selected patients.
Heidenreich A
Eur Urol; 2008 Jul; 54(1):21-3. PubMed ID: 18262722
[No Abstract] [Full Text] [Related]
18. Editorial comment on: Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
von der Maase H
Eur Urol; 2007 Oct; 52(4):1122. PubMed ID: 17433856
[No Abstract] [Full Text] [Related]
19. [Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report].
Furuya Y; Takihana Y; Araki I; Tanabe N; Takeda M
Gan To Kagaku Ryoho; 2003 Jul; 30(7):1017-20. PubMed ID: 12894722
[TBL] [Abstract][Full Text] [Related]
20. Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy.
Tlemcani K; Levine D; Smith RV; Brandwein-Gensler M; Staffenberg DA; Garg MK; Shifteh K; Haigentz M
J Clin Oncol; 2010 Aug; 28(24):e412-4. PubMed ID: 20406935
[No Abstract] [Full Text] [Related]
[Next] [New Search]
